- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the VEGF Pathway in Osteosarcoma
Authors
Keywords
-
Journal
Cells
Volume 10, Issue 5, Pages 1240
Publisher
MDPI AG
Online
2021-05-19
DOI
10.3390/cells10051240
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
- (2020) Antoine Italiano et al. LANCET ONCOLOGY
- Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations
- (2019) Yoshiyuki Suehara et al. CLINICAL CANCER RESEARCH
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
- (2019) Lara E. Davis et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of key genes in osteosarcoma by meta‑analysis of gene expression microarray
- (2019) Junkui Sun et al. Molecular Medicine Reports
- Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study
- (2019) A. Le Cesne et al. EUROPEAN JOURNAL OF CANCER
- Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3
- (2018) Bingxin Zheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study
- (2018) Baorang Zhu et al. CANCER BIOLOGY & THERAPY
- PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
- (2018) Bingxin Zheng et al. Journal of Hematology & Oncology
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
- (2018) M. Fioramonti et al. Scientific Reports
- Pazopanib in relapsed osteosarcoma patients: report on 15 cases
- (2018) Alessandra Longhi et al. ACTA ONCOLOGICA
- Pazopanib in metastatic osteosarcoma patients: Report of 9 cases treated off label at Rizzoli Orthopedic Institute.
- (2018) Alessandra Longhi et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
- (2018) Mark Agulnik et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).
- (2018) Nathalie Gaspar et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-Informed Targeted Therapy for Osteosarcoma
- (2018) Leanne C Sayles et al. Cancer Discovery
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Florence Duffaud et al. LANCET ONCOLOGY
- Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
- (2018) Lu Xie et al. ONCOLOGIST
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
- (2017) Kuisheng Liu et al. Cell Death & Disease
- Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
- (2017) Marco Fioramonti et al. Oncotarget
- Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
- (2017) Zhenhua Zhu et al. Oncotarget
- Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China
- (2017) Feng Li et al. Oncotarget
- Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
- (2016) Joanne P. Lagmay et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison
- (2016) Tracy A. Marko et al. PEDIATRIC BLOOD & CANCER
- Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
- (2015) Mathilde Penel-Page et al. BMC CANCER
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
- (2014) Akmal Safwat et al. ACTA ONCOLOGICA
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) ANNALS OF ONCOLOGY
- Impact of RANK signalling on survival and chemotherapy response in osteosarcoma
- (2014) Zsuzsanna Bago-Horvath et al. PATHOLOGY
- Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience
- (2014) Bong Sup Song et al. PEDIATRIC BLOOD & CANCER
- Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
- (2014) Joost C. M. Uitdehaag et al. PLoS One
- Regulation of mTORC1 by amino acids
- (2014) Liron Bar-Peled et al. TRENDS IN CELL BIOLOGY
- Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience
- (2013) Sarah E. S. Leary et al. CANCER
- Osteosarcoma treatment – Where do we stand? A state of the art review
- (2013) Anja Luetke et al. CANCER TREATMENT REVIEWS
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- New molecular insights into osteosarcoma targeted therapy
- (2013) Jilong Yang et al. CURRENT OPINION IN ONCOLOGY
- Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis
- (2013) Xiao-Wei Yu et al. TUMOR BIOLOGY
- Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy
- (2012) Takaaki Tanaka et al. CLINICAL & EXPERIMENTAL METASTASIS
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma
- (2012) Florence Duffaud et al. EUROPEAN JOURNAL OF CANCER
- TheMEToncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors
- (2012) Nadia Dani et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1
- (2012) Stefano Ferrari et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, includingVEGFA, in human osteosarcoma
- (2011) Jilong Yang et al. CANCER
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model
- (2011) Erik R Sampson et al. JOURNAL OF BONE AND MINERAL RESEARCH
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
- (2010) Karen E. Bullock et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients
- (2009) Berger Massimo et al. CANCER
- mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
- (2009) Quan Zhou et al. MEDICAL ONCOLOGY
- Cell Cycle Regulator Gene CDC5L, a Potential Target for 6p12-p21 Amplicon in Osteosarcoma
- (2008) X.-Y. Lu et al. MOLECULAR CANCER RESEARCH
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started